VRTX241025C470000
- 17.00
- -9.12-34.92%
Vertex Pharmaceuticals Newsroom
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $490 to $600
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $490 to $600
Optimistic Buy Rating for Vertex Pharmaceuticals Amid Promising VX-548 Developments
Vertex Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Vertex Pharmaceuticals, Maintains $600 Price Target
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Korro Bio (KRRO) and Vertex Pharmaceuticals (VRTX)
Analysts Are Neutral on These Healthcare Stocks: CVS Health (CVS), Vertex Pharmaceuticals (VRTX)
Cautious Hold on Vertex Pharmaceuticals Amidst Limited New Insights and Awaited Data
Vertex Pharmaceuticals: Strategic Growth and Promising Drug Development Drive Buy Rating
Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)
UBS Initiates Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $562
Scotiabank Initiates Coverage On Vertex Pharmaceuticals With Sector Perform Rating, Announces Price Target of $480
Vertex Pharmaceuticals Analyst Ratings
Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
Vertex Pharmaceuticals Analyst Ratings
BofA Securities Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Cuts Target Price to $541
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $473 From $474
Vertex Pharmaceuticals (VRTX) Receives a Hold From Morgan Stanley
Raymond James Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating
Vertex Pharmaceuticals Analyst Ratings